Literature DB >> 21309756

Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations.

Laura J Horsfall1, David Zeitlyn, Ayele Tarekegn, Endashaw Bekele, Mark G Thomas, Neil Bradman, Dallas M Swallow.   

Abstract

Variation of a short (TA)(n) repeat sequence (rs8175347) covering the TATA box of UGT1A1 (UDP-glucuronosyltransferase1A1) is associated with hyperbilirubinaemia (Gilbert's syndrome) and adverse drug reactions, and is used for dosage advice for irinotecan. Several reports indicate that the low-activity (risk) alleles ((TA)(7) and (TA)(8) )) are very frequent in Africans but the patterns of association with other variants in the UGT1A gene complex that may modulate these responses are not well known. rs8175347 and two other clinically relevant UGT1A variants (rs11692021 and rs10929302) were assayed in 2616 people from Europe and Africa. Low-activity (TA)(n) alleles frequencies were highest in equatorial Africa, (TA)(7,) being the most common in Cameroon, Ghana, southern Sudan, and in Ethiopian Anuak. Haplotypic diversity was also greatest in equatorial Africa, but in Ethiopia was very variable across ethnic groups. Resequencing of the promoter of a sample subset revealed no novel variations, but rs34547608 and rs887829 were typed and shown to be tightly associated with (TA)(n) . Our results illustrate the need for investigation of the effect of UGT1A variants other than (TA)(n) on the risk of irinotecan toxicity, as well as hyperbilirubinaemia due to hemolytic anaemia or human immunodeficiency virus protease inhibitors, so that appropriate pharmacogenetic advice can be given.
© 2011 The Authors Annals of Human Genetics © 2011 Blackwell Publishing Ltd/University College London.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21309756     DOI: 10.1111/j.1469-1809.2010.00638.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  24 in total

1.  Ethiopian genetic diversity reveals linguistic stratification and complex influences on the Ethiopian gene pool.

Authors:  Luca Pagani; Toomas Kivisild; Ayele Tarekegn; Rosemary Ekong; Chris Plaster; Irene Gallego Romero; Qasim Ayub; S Qasim Mehdi; Mark G Thomas; Donata Luiselli; Endashaw Bekele; Neil Bradman; David J Balding; Chris Tyler-Smith
Journal:  Am J Hum Genet       Date:  2012-06-21       Impact factor: 11.025

2.  The impact of cis-acting polymorphisms on the human phenotype.

Authors:  Bryony L Jones; Dallas M Swallow
Journal:  Hugo J       Date:  2011-07-20

3.  Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.

Authors:  Xun Cai; Chuan Tian; Liwei Wang; Rongyuan Zhuang; Xiaowei Zhang; Yuanbiao Guo; Hongmin Lu; Hui Wang; Xiaoyu Li; Junwei Gao; Qi Li; Chungang Wang
Journal:  Cancer Biol Ther       Date:  2017-02-17       Impact factor: 4.742

4.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

5.  Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

Authors:  Anushka Naidoo; Veron Ramsuran; Maxwell Chirehwa; Paolo Denti; Helen McIlleron; Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Ravesh Singh; Sinaye Ngcapu; Mamoonah Chaudhry; Michael S Pepper; Nesri Padayatchi
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

6.  Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?

Authors:  Catherine J E Ingram; Rosemary Ekong; Naser Ansari-Pour; Neil Bradman; Dallas M Swallow
Journal:  Pharmacogenomics J       Date:  2020-07-18       Impact factor: 3.550

7.  A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus.

Authors:  Satoshi Hiramine; Masaya Sugiyama; Norihiro Furusyo; Hirofumi Uto; Akio Ido; Hirohito Tsubouchi; Hisayoshi Watanabe; Yoshiyuki Ueno; Masaaki Korenaga; Kazumoto Murata; Naohiko Masaki; Jun Hayashi; David L Thomas; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2015-03-05       Impact factor: 7.527

8.  Do Alpha Thalassemia, Fetal Hemoglobin, and the UGT1A1 Polymorphism have an Influence on Serum Bilirubin Levels and Cholelithiasis in Patients with Sickle Cell Disease?

Authors:  Laura Alencastro de Azevedo; Joyce Bonazzoni; Sandrine Comparsi Wagner; Mariela Granero Farias; Christina M Bittar; Liane Daudt; Simone Martins de Castro
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

Review 9.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Authors:  R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas
Journal:  Clin Pharmacol Ther       Date:  2015-11-09       Impact factor: 6.875

10.  Association of UGT1A1 variants and hyperbilirubinemia in breast-fed full-term Chinese infants.

Authors:  Youyou Zhou; San-nan Wang; Hong Li; Weifeng Zha; Xuli Wang; Yuanyuan Liu; Jian Sun; Qianqian Peng; Shilin Li; Ying Chen; Li Jin
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.